There have previously been observational studies showing reduced PCa among users of the anti gout drug allopurinol. Here is a recent study that might explain the observational results.
Xanthine Oxidase/Dehydrogenase Activity as a Source of Oxidative Stress in Prostate Cancer Tissue
by Andrej Veljković 1,*OrcID, Jovan Hadži-Dokić 2, Dušan Sokolović 1OrcID, Dragoslav Bašić 3, Ljubinka Veličković-Janković 3, Marko Stojanović 3, Dejan Popović 3 and Gordana Kocić 1
1 Faculty of Medicine, University of Niš, 18 000 Niš, Serbia
2 Serbian Academy of Sciences and Arts, 11 000 Belgrade, Serbia
3 Clinical Center, 18000 Niš, Serbia
*Author to whom correspondence should be addressed.
Diagnostics 2020, 10(9), 668; doi.org/10.3390/diagnostics...
Received: 30 June 2020 / Revised: 9 August 2020 / Accepted: 28 August 2020 / Published: 3 September 2020
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer 2020)
View Full-Text Download PDF Browse Figures Cite This Paper
Abstract
Prostate cancer (PC) is one of the most frequent malignancies. Better biomarkers are constantly wanted, such as those which can help with the prediction of cancer behavior. What is also needed is a marker which may serve as a possible therapeutic target. Oxidative stress (OS), which is a hallmark of cancer, is included in the pathogenesis and progression of PC. We have conducted the present study to determine whether xanthine oxidase/dehydrogenase activity is the source of OS in prostate tissue. We have also determined the concentration of TBA-reactive substances (TBARS) and advanced oxidation protein products (AOPP), as well as the activity of catalase. Xanthine oxidase (XO) activity is significantly higher (p < 0.001) in tumor tissue when compared to the control healthy tissue. The concentration of TBARS (p < 0.001) and AOPP (p < 0.05) are also higher in tumor tissue. Catalase has raised its activity (p < 0.05) versus the control. There is also a strong correlation between XO activity and prostate-specific antigen (PSA) levels in the serum. These results indicate a significant role of XO activity in OS in prostate carcinogenesis, and it could be a possible theranostic biomarker, which can be important for a better understanding of the disease, its evolution, and prognosis. A promising treatment may be using XO inhibitors such as allopurinol as adjuvant therapy. View Full-Text